Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NorMig: Onabotulinumtoxin A + CGRP mAbs for Chronic Migraine
NCT07040813Phase 3Recruiting
- Sponsor
- Oslo University Hospital
- Start
- Jun 2025
- Primary completion
- Jan 2029
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in chronic migraine, sponsored by Oslo University Hospital. Primary endpoint: Monthly Migraine Days at 12 weeks. Started Jun 2025; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT07040813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07040813.